Lexaria Bioscience Corp.

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
2.97 ^USD	+2.06%		+15.12%	+137.60%

Jul. 12	Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	CI
Jul. 10	HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target	MT

Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2018

January 11, 2019 at 04:38 pm EST

Lexaria Bioscience Corp. announced earnings results for the first quarter ended November 30, 2018. For the first quarter, the company announced sales was USD 22,209 compared to USD 24,635 a year ago. Net loss was USD 701,391 compared to USD 578,713 a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Lexaria Bioscience Corp.

Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	Jul. 12	CI
HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target	Jul. 10	MT
Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2	Jul. 09	CI
Lexaria Bioscience Corp. Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy	Jul. 08	CI
Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents	Jul. 08	MT
Lexaria Bioscience Hires Contract Research Organization For 12-week Study	Jun. 18	MT
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	Jun. 18	CI
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	Jun. 05	CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study	Jun. 05	MT
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	May. 21	MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	May. 17	CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study	May. 08	CI
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs	May. 06	CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	Apr. 16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02	CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	Mar. 14	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	Mar. 14	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05	MT
Sector Update: Health Care	Mar. 05	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	Mar. 05	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	Mar. 05	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04	CI

Chart Lexaria Bioscience Corp.

Duration

Period

More charts

Company Profile

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.97 USD

Average target price

10 USD

Spread / Average Target

+236.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEXARIA BIOSCIENCE CORP.	+137.60%	46.01M
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals